Impact Factor
7.883
Call For Paper
Volume: 11 Issue 02 February 2025
LICENSE
Review: A Novel Drug Firibastat Is First-in-class Brain Aminopeptidase A Inhibitor Treatment On Hypertension
-
Author(s):
Ajay Bhojane | Dipak Ghodekar | Vikas Kandekar | Narendra Gowekar
-
Keywords:
Hypertension, Aminopeptidase, Stimulation, Quantum Genomics
-
Abstract:
Firibastat Is The New First-in-class Centrally Acting Aminopeptidase A Inhibitor Prodrug. Pharmacologically, Firibastat Prevents The Conversion Of Angiotensin-II To Angiotensin-III, One Of The Main Effector Peptides Of The Brain Renin–angiotensin System
Other Details
-
Paper id:
IJSARTV8I654930
-
Published in:
Volume: 8 Issue: 6 June 2022
-
Publication Date:
2022-06-02
Download Article